Erythrocytosis and Elevated Hematocrit on TRT: Causes, Risks, and Management

What Is Erythrocytosis in the Context of TRT?

Erythrocytosis means an abnormal increase in circulating red blood cells, measured clinically as a rise in hematocrit (the percentage of blood volume occupied by red cells) or hemoglobin concentration. On TRT, this is the single most common adverse hematologic finding. A 2010 meta-analysis of 51 randomized controlled trials published in the Journal of Clinical Endocrinology and Metabolism found that men receiving testosterone were 3.67 times more likely to develop erythrocytosis than men receiving placebo [1]. That number should anchor every discussion of TRT safety.

Normal hematocrit for adult men sits between 38.3% and 48.6% [2]. Values above 52% are considered elevated; above 54% they cross the threshold at which the Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy explicitly recommends withholding or reducing testosterone until the value falls [3]. Blood viscosity rises non-linearly past that point, increasing shear stress on vessel walls and slowing flow through smaller vessels.

Erythrocytosis is not the same as polycythemia vera, the myeloproliferative neoplasm driven by JAK2 mutations. Secondary erythrocytosis from TRT is dose-dependent and generally reversible. The distinction matters because treatment differs entirely.

Why Does Testosterone Raise Hematocrit?

Testosterone stimulates red cell production through at least two parallel pathways. First, it directly increases renal erythropoietin (EPO) secretion. Second, it suppresses hepcidin, the liver-derived peptide that normally limits iron availability for erythropoiesis [4]. With hepcidin suppressed, more iron reaches the bone marrow. Erythroid precursors proliferate faster. The net effect is a measurable rise in hematocrit that can begin within 4 to 6 weeks of starting therapy.

Delivery route matters. Intramuscular injections of testosterone cypionate or enanthate produce large peak-to-trough swings in serum testosterone, pushing EPO secretion hard during the peak phase. Transdermal gels produce steadier, lower peaks. A prospective comparison published in Clinical Endocrinology found that injectable testosterone produced significantly higher rates of hematocrit elevation above 50% compared with transdermal formulations over 12 months [5]. Testosterone pellets implanted subcutaneously behave similarly to injectables due to their high and sustained release.

Higher doses and higher resulting serum testosterone levels amplify the effect. Men whose trough testosterone levels are pushed above the physiologic ceiling (roughly 1 to 100 ng/dL) are at the greatest risk.

What Hematocrit Level Requires Action?

The Endocrine Society 2018 guideline states: "We suggest withholding testosterone therapy until hematocrit decreases to a safe level" when hematocrit exceeds 54% [3]. The American Urological Association's 2018 testosterone deficiency guidelines use the same 54% threshold as a hard stop [6].

Hematocrit between 50% and 54% sits in a monitoring zone. Some clinicians intervene at 52% in men who also have cardiovascular risk factors such as atrial fibrillation, prior DVT, or metabolic syndrome. The logic is straightforward: above 52%, blood viscosity increases enough to slow microvascular flow, and venous thromboembolism risk rises by approximately 30% in TRT-treated cohorts [7].

A complete blood count (CBC) at baseline, then at 3 months and 6 months after starting therapy, catches the majority of cases before they reach 54%. Annual CBC checks are appropriate once hematocrit has been stable for two consecutive measurements.

Clinical Management of TRT-Related Erythrocytosis

Four interventions reduce hematocrit in TRT-related erythrocytosis, and most men need only one or two of them.

Dose reduction. Lowering the weekly testosterone dose by 20 to 30% typically drops hematocrit by 2 to 4 percentage points within 8 to 12 weeks. This is the first option when hematocrit is between 52% and 54% and the patient wants to continue therapy.

Route switch. Moving from intramuscular cypionate to a daily transdermal gel or to testosterone nasal gel (Natesto) reduces peak EPO stimulation. Men who switch from every-two-week injections to twice-weekly lower-dose injections often see a similar benefit because the peak is blunted.

Extended dosing interval. Stretching injections from every 7 days to every 10 or 14 days while lowering the per-dose amount keeps total weekly testosterone delivery lower, trimming the erythropoietic stimulus.

Therapeutic phlebotomy. When hematocrit exceeds 54%, or when it sits above 52% and does not respond to dose adjustments within 8 weeks, phlebotomy (removing 1 unit of whole blood, approximately 450 to 500 mL) rapidly reduces hematocrit by 3 to 5 percentage points [8]. Many centers perform a second phlebotomy 4 to 6 weeks later if the initial drop is insufficient. Phlebotomy is not a substitute for addressing the underlying dose issue, because erythrocytosis will recur if testosterone doses stay high.

The decision tree that HealthRX clinicians use at each monitoring visit:

1. Hematocrit <50%: continue current regimen, recheck in 6 months.
2. Hematocrit 50 to 52%: recheck in 8 weeks; ensure hydration is adequate; consider modest dose reduction.
3. Hematocrit 52 to 54%: reduce dose or switch route; recheck CBC in 8 weeks.
4. Hematocrit >54%: hold testosterone; perform phlebotomy; recheck in 4 weeks; restart at lower dose only after value falls below 50%.

TRT and Cardiovascular Risk: What the Evidence Actually Shows

The relationship between TRT and cardiovascular events was murky for a decade after a 2010 NEJM trial (the Testosterone in Older Men with Mobility Limitations study) was stopped early due to excess cardiovascular events in the treatment group [9]. Later analyses pointed to design flaws and the inclusion of men with pre-existing severe cardiac disease.

The TRAVERSE trial, published in the New England Journal of Medicine in 2023, settled the central question for most clinicians. TRAVERSE enrolled 5,246 hypogonadal men aged 45 to 80 with elevated cardiovascular risk and randomized them to testosterone gel 1.62% or placebo for a mean of 33 months [10]. The primary cardiovascular composite endpoint (MACE: death, non-fatal MI, non-fatal stroke) was non-inferior in the testosterone arm (7.0% vs. 7.3% placebo). This is the largest cardiovascular safety trial of TRT conducted to date.

TRAVERSE did not exonerate TRT entirely. The testosterone arm had higher rates of atrial fibrillation (3.5% vs. 2.4%) and pulmonary embolism (0.9% vs. 0.5%) [10]. Both findings are biologically plausible given the erythrocytosis mechanism described above. Men with pre-existing atrial fibrillation or prior venous thromboembolism require individualized risk-benefit assessment before starting TRT.

The American Heart Association notes that secondary erythrocytosis from any cause is a recognized contributor to arterial and venous thrombosis [11]. Managing hematocrit is therefore inseparable from managing cardiovascular safety on TRT.

TRT and Prostate Cancer Risk

Fear of prostate cancer has historically been the single largest barrier to TRT prescribing. The fear traces back to a 1941 case series by Huggins and Hodges showing that castration caused prostate cancer regression, which was read in reverse as proof that testosterone fuels prostate cancer growth. That reading drove clinical practice for six decades.

Current evidence does not support withholding TRT solely because of prostate cancer concern in men without a diagnosed or suspected prostate malignancy. A 2016 systematic review in European Urology examined 22 controlled trials and found no statistically significant increase in prostate cancer incidence in testosterone-treated men compared with placebo over follow-up periods ranging from 6 to 36 months [12]. PSA rises modestly in the first 3 to 6 months on TRT, typically by less than 0.5 ng/mL, and then stabilizes.

The Endocrine Society 2018 guideline states: "We suggest measuring PSA and performing digital rectal examination in men over 40 years of age before initiating testosterone therapy" [3]. PSA should be rechecked at 3 to 6 months after starting, then annually. A rise above 1.4 ng/mL from baseline within the first 12 months, or any PSA exceeding 4.0 ng/mL (or 3.0 ng/mL in high-risk populations), warrants urology referral before continuing TRT.

Active or suspected prostate cancer remains an absolute contraindication. Men with prostate cancer who have undergone definitive treatment are sometimes considered candidates for TRT under specialist supervision, but that falls outside standard TRT protocols.

TRT and Benign Prostatic Hyperplasia

Testosterone does not cause BPH, but it may worsen lower urinary tract symptoms (LUTS) in men who already have it. The mechanism is indirect: testosterone converts to dihydrotestosterone (DHT) via 5-alpha reductase in prostate tissue, and DHT is the primary androgen driving prostate stromal growth.

A 12-month randomized trial published in The Journal of Urology found no significant worsening of IPSS (International Prostate Symptom Score) in men with mild to moderate BPH who received TRT versus placebo [13]. Men with severe LUTS (IPSS above 19) were excluded. The practical takeaway is that mild to moderate BPH is not an absolute contraindication to TRT, but severe LUTS or significant post-void residual volume should prompt a urology evaluation before treatment begins.

Prostate volume should be measured at baseline (via ultrasound or MRI) in men with known BPH who want to start TRT. Annual IPSS questionnaire monitoring is reasonable. Men taking 5-alpha reductase inhibitors such as finasteride or dutasteride for BPH may actually see less DHT-driven prostate stimulation during TRT, which can simplify the risk picture.

Monitoring Schedule and Lab Targets on TRT

Systematic monitoring prevents the majority of TRT complications. The table below reflects the Endocrine Society 2018 guideline and the AUA 2018 testosterone deficiency guideline, adapted for the HealthRX clinical workflow.

| Timepoint | Labs Required | Clinical Check | |---|---|---| | Baseline | Total T, free T, LH, FSH, CBC, PSA, CMP, estradiol, lipids | BP, weight, DRE (age >40) | | 3 months | Total T, CBC, PSA, estradiol | Symptom review, BP | | 6 months | Total T, CBC, PSA, CMP | Weight, BP | | 12 months | Full panel as baseline | DRE (age >40), IPSS if BPH | | Annually thereafter | Total T, CBC, PSA, CMP | As above |

Target serum testosterone for most men on TRT is the mid-normal range, roughly 400 to 700 ng/dL for total testosterone in the morning. Supraphysiologic levels above 1 to 100 ng/dL provide no added symptom benefit and substantially increase erythrocytosis risk. Estradiol should stay between 20 and 40 pg/mL to preserve bone density and libido while avoiding gynecomastia.

Lifestyle Factors That Modify Erythrocytosis Risk

Dehydration raises hematocrit acutely by reducing plasma volume without changing red cell mass. A man who runs a 10K before his CBC draw may show a falsely elevated hematocrit. Clinicians should instruct patients to hydrate normally the morning of lab tests and avoid vigorous exercise in the 24 hours prior.

Sleep apnea independently stimulates erythropoiesis through chronic nocturnal hypoxia. Men on TRT who have untreated obstructive sleep apnea often develop erythrocytosis despite moderate testosterone doses. A 2019 analysis in the Journal of Clinical Sleep Medicine found that men with both TRT and untreated OSA had nearly twice the rate of hematocrit elevation above 52% compared to men on TRT alone [14]. Screening for and treating sleep apnea before or alongside TRT reduces erythrocytosis risk meaningfully.

Altitude of residence also matters. Men living above 6,000 feet have baseline hematocrit values that run 1 to 3 percentage points higher than sea-level norms. Their intervention thresholds may need individual calibration.

Tobacco smoking promotes secondary erythrocytosis through carboxyhemoglobin-driven tissue hypoxia. Men who smoke and take TRT face additive erythrocytosis risk. Smoking cessation counseling belongs in every TRT intake visit.

Fertility Considerations and Spermatogenesis

TRT suppresses the hypothalamic-pituitary-gonadal axis by replacing exogenous testosterone, which eliminates the LH and FSH drive to the testes. Intratesticular testosterone drops to near zero within weeks, causing significant azoospermia or severe oligospermia in most men [15]. This is relevant beyond reproductive goals because it also causes testicular atrophy, which is a source of patient distress.

Men who want to preserve fertility should not use standard TRT. Human chorionic gonadotropin (hCG), clomiphene citrate, or a combination protocol maintains intratesticular testosterone and sperm production while treating hypogonadal symptoms. Adding hCG 500 IU twice weekly to TRT has been shown to maintain testicular size and preserve some sperm production in about 50% of men [15].

Sperm banking before starting TRT is the most reliable fertility preservation strategy for men who may want children in the future.

Comparing TRT Delivery Routes by Erythrocytosis Risk

Not all TRT formulations carry equal erythrocytosis risk. The data favor lower-risk routes for men who already have hematocrit above 48% at baseline or who have other cardiovascular risk factors.

Intramuscular testosterone cypionate or enanthate (every 1 to 2 weeks): Highest erythrocytosis risk due to large peak levels. Twice-weekly dosing at lower per-dose amounts (e.g., 50 mg twice weekly instead of 100 mg weekly) reduces peaks and lowers risk.

Testosterone gels (AndroGel 1.62%, Testim, Vogelxo): Moderate erythrocytosis risk. Daily application maintains steadier levels. Skin-to-skin transfer to partners or children is a real but manageable concern.

Testosterone nasal gel (Natesto 4.5 mg per actuation, three times daily): Lowest erythrocytosis risk in head-to-head data. A 90-day study found Natesto produced no statistically significant change in hematocrit compared to baseline, while maintaining LH and FSH better than other routes, preserving more spermatogenesis [16].

Subcutaneous testosterone pellets (Testopel): Risk profile similar to intramuscular. Pellets release over 3 to 6 months and cannot be removed if complications arise, making them a poor choice for men prone to erythrocytosis.

Oral testosterone undecanoate (Jatenzo, Tlando): Moderate risk. Absorbed via lymphatics, bypassing first-pass hepatic metabolism. Clinical trial data show hematocrit increases of approximately 3 to 5 percentage points over 12 months, comparable to transdermal gels [17].